VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY A CONTROLLING SHAREHOLDER
14/12/2021 20:54
Link
SEHK
pdf
01745
LVJI TECH
(1) CHANGE OF CHIEF FINANCIAL OFFICER; AND (2) CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVES
14/12/2021 20:52
Link
SEHK
pdf
06611
SANXUN GROUP
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
14/12/2021 20:42
Link
SEHK
htm
01839
CIMC VEHICLES
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION ACQUISITION OF EQUITY INTERESTS IN CH-AUTO TECHNOLOGY
14/12/2021 20:37
Link
SEHK
pdf
00527
RUIFENG RENEW
US$250,000,000 4.5% Notes Due September 2023 - Purchase and Cancellation of Part of the Notes
14/12/2021 20:32
Link
SEHK
pdf
00163
EMPEROR INT'L
ANNOUNCEMENT ON THE RECEIPT OF "CIVIL MEDIATION DOCUMENT" BY BEIJING TAINHAI CRYOGENIC EQUIPMENT CO., LTD.
14/12/2021 20:29
Link
SEHK
pdf
00187
JINGCHENG MAC
List of Directors and Their Roles and Functions
14/12/2021 20:27
Link
SEHK
pdf
03808
SINOTRUK
CHANGES OF NON-EXECUTIVE DIRECTORS
14/12/2021 20:23
Link
SEHK
pdf
03808
SINOTRUK
CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
14/12/2021 20:19
Link
SEHK
pdf
02175
CH GENERAL EDU
Grant of Share Options
14/12/2021 20:15
Link
SEHK
pdf
00210
DAPHNE INT'L
Voluntary Announcement - Ascentage Pharma Presents Results of Six Studies of Three Novel Drug Candidates under Development (Olverembatinib, APG-2575, and APG-1252) at the 63rd American Society of Hematology (ASH) Annual Meeting
14/12/2021 20:08
Link
SEHK
pdf
06855
ASCENTAGE-B
SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION IN RELATION TO THE FORMATION OF PROJECT COMPANY UNDER THE COOPERATION FRAMEWORK AGREEMENT
14/12/2021 20:02
Link
SEHK
pdf
03728
CHING LEE
GRANT OF RSU PURSUANT TO THE 2021 RSU SCHEME
14/12/2021 20:02
Link
SEHK
pdf
01739
QEEKA HOME
DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (I) PROPOSED RIGHTS ISSUE ON THE BASIS OF TWO RIGHTS SHARES FOR EVERY ONE EXISTING SHARE HELD ON THE RECORD DATE; (II) CONNECTED TRANSACTIONS IN RELATION TO THE UNDERWRITING AGREEMENT AND SET OFF OF SHAREHOLDER'S LOANS; (III) APPLICATION FOR WHITEWASH WAIVER; AND (IV) NOTICE OF EXTRAORDINARY GENERAL MEETING
14/12/2021 20:02
Link
SEHK
pdf
02363
TONGDA HONG TAI
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
14/12/2021 19:58
Link
SEHK
htm
02880
LIAONING PORT
(1) CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF 51% EQUITY INTEREST IN ZHEJIANG GREENTOWN ARCHITECTURAL TECHNOLOGY CO., LTD* AND (2) POSSIBLE CONTINUING CONNECTED TRANSACTION IN RELATION TO THE FRAMEWORK COOPERATION AGREEMENT
14/12/2021 19:57
Link
SEHK
pdf
02869
GREENTOWN SER
Attachments
Original Link
Original Document
Permalink
Disclaimer
China Medical System Holdings Ltd. published this content on 14 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 December 2021 13:27:02 UTC.
China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.